US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-22 01:51:41 Source：World Wander news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：Trump or Biden? Either way, US seems poised to preserve heavy tariffs on imports
- Next：DR MARTIN SCURR: How losing your hearing may cause dementia
Related articles
- Brewers starter Joe Ross leaves after first inning vs. Marlins with lower back strain
- China boasts 2 mln beds in integrated medical, elderly care institutions
- China ready to launch Chang'e
- Ana Dias, Olivia Moultrie give Thorns sixth straight NWSL win
- China vows to actively promote restoration of int'l flights
- China maps out key tasks in digitalizing countryside
- Chinese scientists create multi
- 'Snow Town' attracting tourists to Heilongjiang
- Xander Schauffele gets validation and records with one memorable putt at PGA Championship
- Chinese scientists create multi
- Eleanor Tomlinson puts on a leggy display in sparkly black minidress as she joins co
- China to establish national park at Qinghai Lake
- China issues alert for geomagnetic storm
- Brown v. Board: Even with school choice, some Black families find options lacking
- MPs' fury at 'virtue
- Ana Dias, Olivia Moultrie give Thorns sixth straight NWSL win
- China's top legislature starts standing committee session
- Suzhou taps into international travel market
- Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
- Chinese scientists achieve breakthrough in combating plant cancer
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Wander news portal sitemap